Use of zoledronic acid in antiosteoporosis treatment is associated with a decreased blood lipid level in postmenopausal women with osteoporosis: a cohort study in China

References

• Clynes MA, Harvey NC, Curtis EM, et al. The epidemiology of osteoporosis. Br Med Bull. 2020;133(1):105–117.
   PubMed Web of Science ®Google Scholar
• Anastasilakis AD, Polyzos SA, Makras P. THERAPY OF ENDOCRINE DISEASE: denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis.Eur J Endocrinol. 2018;179(1):R31–R45.
   PubMed Web of Science ®Google Scholar
• During A. Osteoporosis: a role for lipids. Biochimie. 2020;178:49–55.
   PubMed Web of Science ®Google Scholar
• Hernlund E, Svedbom A, Ivergrd M, et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. a report prepared in collaboration with the International Osteoporosis Foundation (iOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA).Arch Osteoporos. 2013;8(1–2):136.
   PubMed Web of Science ®Google Scholar
• Tian L, Yang R, Wei L, et al. Prevalence of osteoporosis and related lifestyle and metabolic factors of postmenopausal women and elderly men: a cross-sectional study in Gansu province, Northwestern of China. Medicine (Baltimore). 2017;96(43):e8294.
   PubMed Web of Science ®Google Scholar
• Polyzos SA, Anastasilakis AD, Efstathiadou ZA, et al. Postmenopausal osteoporosis coexisting with other metabolic diseases: treatment considerations. Maturitas. 2021;147:19–25.
   PubMed Web of Science ®Google Scholar
• Musso G, Paschetta E, Gambino R, et al. Interactions among bone, liver, and adipose tissue predisposing to diabesity and fatty liver. Trends Mol Med. 2013;19(9):522–535.
   PubMed Web of Science ®Google Scholar
• Alay I, Kaya C, Cengiz. H; et al. The relation of body mass index, menopausal symptoms, and lipid profile with bone mineral density in postmenopausal women. Taiwan J Obstet Gynecol. 2020;59(1):61–66.
   Google Scholar
• Manzoni AG, Passos DF, Doleski PH, et al. Purine metabolism in platelets and heart cells of hyperlipidemic rats. Cardiovasc Drugs Ther. 2020;34(6):813–821.
   PubMed Web of Science ®Google Scholar
• Fisher JE, Rodan GA, Reszka AA. In vivo effects of bisphosphonates on the osteoclast mevalonate pathway. Endocrinology. 2000;141(12):4793–4796.
   PubMed Web of Science ®Google Scholar
• Gong L, Altman RB, Klein TE. Bisphosphonates pathway. Pharmacogenet Genomics. 2011;21(1):50–53.
   PubMed Web of Science ®Google Scholar
• Qaseem A, Forciea MA, McLean RM, et al. Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of Physicians. Ann Intern Med. 2017;166(11):818–839.
   PubMed Web of Science ®Google Scholar
• Hasan WNW, Chin KY, Jolly JJ, et al. Identifying potential therapeutics for osteoporosis by exploiting the relationship between mevalonate pathway and bone metabolism. Endocr Metab Immune Disord Drug Targets. 2018;18(5):450–457.
   PubMed Web of Science ®Google Scholar
• Guney E, Kisakol G, Ozgen AG, et al. Effects of bisphosphonates on lipid metabolism. Neuro Endocrinol Lett. 2008;29(2):252–255.
   PubMed Web of Science ®Google Scholar
• Adami S, Braga V, Guidi G, et al. Chronic intravenous amino bisphosphonate therapy increases high-density lipoprotein cholesterol and decreases low-density lipoprotein cholesterol. J Bone Miner Res. 2000;15(3):599–604.
   PubMed Web of Science ®Google Scholar
• Kondo M, Mizuno Y. [Bone metabolism and cardiovascular function update. effects of antiosteoporotic agents on glucose and lipid metabolism]. Clin Calcium. 2014;24(7):93–97.
   PubMedGoogle Scholar
• Gong L, Altman RB, Klein TE. Bisphosphonates pathway. Pharmacogenet Genomics. 2011;21(1):50–53.
   PubMed Web of Science ®Google Scholar
• Luckman SP, Hughes DE, Coxon FP, et al. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res. 1998;13(4):581–589.
   PubMed Web of Science ®Google Scholar
• Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature. 1990;343(6257):425–430.
   PubMed Web of Science ®Google Scholar
• Lennernas H, Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin Pharmacokinet. 1997;32(5):403–425.
   PubMed Web of Science ®Google Scholar
• Chao M, Hua Q, Yingfeng Z, et al. Study on the role of zoledronic acid in treatment of postmenopausal osteoporosis women. Pak J Med Sci. 2013;29(6):1381–1384.
   PubMed Web of Science ®Google Scholar
• Bonnick S, Broy S, Kaiser F, et al. Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density. Curr Med Res Opin. 2007;23(6):1341–1349.
   PubMed Web of Science ®Google Scholar
• Adami S, Bertoldo F, Braga V, et al. 25-Hydroxy vitamin D levels in healthy premenopausal women: association with bone turnover markers and bone mineral density. Bone. 2009;45(3):423–426.
   PubMed Web of Science ®Google Scholar
• Need AG. Bone resorption markers in vitamin D insufficiency. Clin Chim Acta. 2006;368(1–2):48–52.
   PubMed Web of Science ®Google Scholar
• Asemi Z, Foroozanfard F, Hashemi T, et al. Calcium plus vitamin D supplementation affects glucose metabolism and lipid concentrations in overweight and obese vitamin D deficient women with polycystic ovary syndrome. Clin Nutr. 2015;34(4):586–592.
   PubMed Web of Science ®Google Scholar
• Chai W, Cooney RV, Franke AA, et al. Effects of calcium and vitamin D supplementation on blood pressure and serum lipids and carotenoids: a randomized, double-blind, placebo-controlled, clinical trial. Ann Epidemiol. 2013;23(9):564–570.
   PubMed Web of Science ®Google Scholar
• Rajpathak SN, Xue X, Wassertheil-Smoller S, et al. Effect of 5 y of calcium plus vitamin D supplementation on change in circulating lipids: results from the Women’s Health Initiative.Am J Clin Nutr. 2010;91(4):894–899.
   PubMed Web of Science ®Google Scholar
• Dibaba DT. Effect of vitamin D supplementation on serum lipid profiles: a systematic review and meta-analysis. Nutr Rev. 2019;77(12):890–902.
   PubMed Web of Science ®Google Scholar
• Jafari T, Fallah AA, Barani A. Effects of vitamin D on serum lipid profile in patients with type 2 diabetes: a meta-analysis of randomized controlled trials. Clin Nutr. 2016;35(6):1259–1268.
   PubMed Web of Science ®Google Scholar
• Qin XF, Zhao LS, Chen WR, et al. Effects of vitamin D on plasma lipid profiles in statin-treated patients with hypercholesterolemia: a randomized placebo-controlled trial. Clin Nutr. 2015;34(2):201–206.
   PubMed Web of Science ®Google Scholar
• Munoz-Aguirre P, Flores M, Macias N, et al. The effect of vitamin D supplementation on serum lipids in postmenopausal women with diabetes: a randomized controlled trial. Clin Nutr. 2015;34(5):799–804.
   PubMed Web of Science ®Google Scholar
• Wang XX, Jiang T, Shen Y, et al. Vitamin D receptor agonist doxercalciferol modulates dietary fat-induced renal disease and renal lipid metabolism. Am J Physiol Renal Physiol. 2011;300(3):F801–10.
   PubMed Web of Science ®Google Scholar
• Li S, He Y, Lin S, et al. Increase of circulating cholesterol in vitamin D deficiency is linked to reduced vitamin D receptor activity via the Insig-2/SREBP-2 pathway. Mol Nutr Food Res. 2016;60(4):798–809.
   PubMed Web of Science ®Google Scholar
• Vítek L. The role of bilirubin in diabetes, metabolic syndrome, and cardiovascular diseases. Front Pharmacol. 2012;3:55.
   PubMed Web of Science ®Google Scholar